Sanofi-aventis has joined the league of big pharma targeting infectious diseases by entering into collaboration with Alopexx Pharmaceuticals to produce a novel antibody. This deal was preceded by a research cooperation agreement with Caltech and one with The Rockefeller University for an antibody to treat Alzheimer’s disease.